The short version of GIP receptor fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-02-21 and is reviewed periodically as new material appears.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
| Property | Value | Notes |
|---|---|---|
| Typical supplied form | Lyophilized powder | Hygroscopic, seal promptly after opening |
| Long-term storage temperature | At or below minus 20 C | Protect from repeated freeze-thaw |
| Working solution stability | Hours when refrigerated | Use within the same working day |
| Primary purity method | Reversed-phase HPLC | Often paired with mass spectrometry |
| Aggregate measurement | Size-exclusion chromatography | Reports high-molecular-weight species |
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.
Common degradation routes include hydrolysis of labile amide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation. Aggregates can form during freeze-thaw cycling, at elevated pH, or when peptide concentration is high. Each route produces characteristic chromatographic or mass shifts that are tracked during stability studies. Whether a given minor impurity alters biological activity is often an open question, and specification limits are typically set on identity and purity rather than on functional data for trace species.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
Current issues for the CV reside in outbreaks of violence with criminal organizations for control of drug routes and turf wars with militias over territories, such as the Complexo do Alemão (which is sometimes considered the "headquarters" of the organization).
== Nomenclature and terminology == The nomenclature of the metal carbonyls depends on the charge of the complex, the number and type of central atoms, and the number and type of ligands and their binding modes. They occur as neutral complexes, as positively-charged metal carbonyl cations or as negatively charged metal carbonylates. The carbon monoxide ligand may be bound terminally to a single metal atom or bridging to two or more metal atoms. These complexes may be homoleptic, containing only CO ligands, such as nickel tetracarbonyl (Ni(CO)4), but more commonly metal carbonyls are heteroleptic and contain a mixture of ligands. Mononuclear metal carbonyls contain only one metal atom as the central atom. Except vanadium hexacarbonyl, only metals with even atomic number, such as chromium, iron, nickel, and their homologs, build neutral mononuclear complexes. Polynuclear metal carbonyls are formed from metals with odd atomic numbers and contain a metal–metal bond. Complexes with different metals but only one type of ligand are called isoleptic. Carbon monoxide has distinct binding modes in metal carbonyls. They differ in terms of their hapticity, denoted η, and their bridging mode. In η2-CO complexes, both the carbon and oxygen are bonded to the metal. More commonly only carbon is bonded, in which case the hapticity is not mentioned. The carbonyl ligand engages in a wide range of bonding modes in metal carbonyl dimers and clusters. In the most common bridging mode, denoted μ2 or simply μ, the CO ligand bridges a pair of metals.
== History == MrMed was conceived in August 2020 when Devashish Singh and Saurab Jain noticed challenges in specialty medicines. Despite facing initial setbacks due to the COVID Delta wave in India, which prompted the founders and their team to prioritize community assistance, MrMed was officially launched in June 2021. The company launched its mobile app in March 2023 for access to speciality medicines for conditions such as cancer, transplants, kidney, or liver diseases. It also raised $500,000 in funding from the Tamil Nadu Emerging Sector Seed Fund (TNESSF) and angel investors. On 8 December 2025, the company announced a strategic partnership with the American multinational pharmaceutical company Eli Lilly to support the distribution of specialty medicines in India.
== Live foods == Live foods are based on small living creatures in their recognizable form and can be either still living, dried or frozen. Live fish food include earthworms, sludge worms, water fleas, bloodworms, and feeder fish. Food for larvae and young fish include infusoria (Protozoa and other microorganisms), newly hatched brine shrimp and microworms. These are the most preferred type of food for fish, but are difficult to get and can be quite expensive. However, freeze dried forms of earthworms, tubifex etc. are available now.
Travellers require a biometric passport to use SmartGate as it uses information from the passport (such as photograph, name and date of birth) and in the respective countries' databases (i.e. banned travellers database) to decide whether to grant entry or departure from Australia or to generate a referral to a customs agent. These checks would otherwise require manual processing by a human, which is time-consuming, costly, and potentially error-prone. UK and Ireland: ePassport gates in the UK and Ireland are operated by the UK Border Force and the Irish Naturalisation and Immigration Service, and are located at immigration checkpoints in the arrival halls of some airports across both countries, offering an alternative to using desks staffed by immigration officers. The gates use a facial recognition system to verify the user's identity by comparing their facial features to those recorded in the photograph stored on the chip of their biometric passport. British citizens, European Economic Area citizens and citizens of Australia, Canada, Japan, New Zealand, Singapore, South Korea, Taiwan and the United States as well as Chinese citizens of Hong Kong who are enrolled in the Registered Traveller Service, can use ePassport gates at 14 ports of entry in the United Kingdom provided that they are aged either 18 and over or 12 and over, travelling with an adult and holding valid biometric passports.
Sources: en.wikipedia.org
Pasteur effect Also Pasteur-Meyerhof effect. A phenomenon observed in facultatively anaerobic cells, including animal tissues and many microorganisms such as yeast, whereby the presence of oxygen in the environment inhibits the cell's use of ethanol fermentation pathways to generate energy, and drives the cell to instead make use of the available oxygen in aerobic respiration; or more generally the observed decrease in the rate of glycolysis or of lactate production in cells exposed to oxygenated air.
Historically, Romanian researchers and inventors have made notable contributions to several fields. In the history of flight, Traian Vuia built the first aeroplane to take off under its own power and Aurel Vlaicu built and flew some of the earliest successful aircraft, while Henri Coandă discovered the Coandă effect of fluidics. Victor Babeș discovered more than 50 types of bacteria; biologist Nicolae Paulescu developed an extract of the pancreas and showed that it lowers blood sugar in diabetic dogs, thus being significant in the history of insulin; while Emil Palade received the Nobel Prize for his contributions to cell biology. Lazăr Edeleanu was the first chemist to synthesise amphetamine, and he also invented the procedure of separating valuable petroleum components with selective solvents. During the 1990s and 2000s, the development of research was hampered by several factors, including corruption, low funding, and a considerable brain drain. In recent years, Romania has ranked the lowest or second-lowest in the EU by research and development spending as a percentage of GDP, standing at roughly 0.5% in 2016 and 2017, substantially below the EU average of just over 2%. The country joined the European Space Agency (ESA) in 2011, and CERN in 2016. In 2018, however, Romania lost its voting rights in the ESA due to a failure to pay €56.8 million in membership contributions to the agency. In the early 2010s, the situation for science in Romania was characterised as "rapidly improving" albeit from a low base.
Huntington's or Huntington disease (HD), also known as Huntington's chorea, is a fatal neurodegenerative disease that is usually inherited. It typically presents as a triad of progressive psychiatric, cognitive, and motor symptoms. The earliest symptoms are often subtle problems with mood or mental/psychiatric abilities, which precede the motor symptoms for many people. The definitive physical symptoms, including a general lack of coordination and an unsteady gait, eventually follow. Over time, the basal ganglia region of the brain gradually becomes damaged. The disease is primarily characterized by a distinctive hyperkinetic movement disorder known as chorea. Chorea classically presents as uncoordinated, involuntary, "dance-like" body movements that become more apparent as the disease advances. Physical abilities gradually worsen until coordinated movement becomes difficult and the person is unable to talk. Mental abilities generally decline into dementia, depression, apathy, and impulsivity at times. The specific symptoms vary somewhat among cases. Symptoms can start at any age, but are usually first seen around the age of 40. The disease may develop earlier in each successive generation. About eight percent of cases start before the age of 20 years, and are known as juvenile HD, which typically present with the slow movement symptoms of Parkinson's disease rather than those of chorea. HD is typically inherited from an affected parent, who carries a mutation in the huntingtin gene (HTT), which encodes the huntingtin protein.
Subdural fluid collections Enhancement of the meninges Engorgement of venous structures Pituitary swelling Sagging of the brain For suspected spinal CSF leaks, spine imaging can be used to guide treatment.
Sources: en.wikipedia.org
Water promotes hydrolysis and deamidation, so removing it slows degradation during transport and storage. The dry solid is also less prone to microbial growth than a solution. Reconstitution is therefore performed close to the point of use.
Reversed-phase high-performance liquid chromatography is the standard method for purity and related substances. It separates the main peak from deletion sequences and oxidation products. Mass spectrometry is frequently used alongside it to confirm molecular identity.
Aggregates, truncated sequences, and oxidation products receive the most attention. Size-exclusion chromatography covers aggregates, while reversed-phase methods resolve many chemical variants. Limits are set according to the route of administration and the expected exposure.
It is a synthetic linear peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It combines a modified incretin backbone with a fatty diacid side chain that extends its circulation time. It is not a small-molecule drug and is not orally absorbed in its native form.